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The recent availability of cDNA clones for pemphigus antigens has allowed the production of recombinant desmoglein 1 and
desmoglein 3 molecules and the development of an ELISA approach in order to determine levels of antibodies to them. The aim
of the study was to determine the relationship between autoantibodies levels and the extent of both mucosal and skin lesions in
20 patients with pemphigus vulgaris at the time of diagnosis and during follow-up. For the detection of autoantibodies by ELISA
we used the recombinant proteins expressing overlapping sequences with the entire extracellular desmoglein 1 and desmoglein
3 domains. We showed that in presence of mucosal lesions there was a correlation between extension of mucosal involvement
and autoantiboidies titres against both desmoglein 1 and desmoglein 3, whereas in presence of skin lesions there was a statistically
signiﬁcantcorrelationbetweenextensionofskinlesionsandautoantibodiestitresagainstdesmoglein3,butnotagainstdesmoglein
1. A not negligible number of patients showed variations of the desmoglein 3 autoantibodies titre which did not correlate with
the severity of both cutaneous and mucosal involvement. Similar results were obtained analyzing autoantibodies titres against
desmoglein 1. In conclusion, we believe that the utilization of recombinant desmoglein 1 and desmoglein 3 proteins by ELISA
should be used with caution to monitor disease severity and response to therapy, although it remains a high speciﬁc test for the
initial diagnosis of pemphigus and the identiﬁcation of a change in the clinical phenotype of this condition.
Copyright © 2009 Anna Belloni-Fortina et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Pemphigus is a group of human autoimmune blistering
disorders characterized by autoantibodies directed against
transmembrane desmosomal proteins of keratinocytes called
desmogleins(DSGs),resultinginlossofthenormalepithelial
cell-to-cell adhesion, through a process called acantholysis
[1]. The two main subtypes of pemphigus are pemphigus
vulgaris (PV) and pemphigus foliaceous (PF), and they
have distinct clinical, histological, and immunopathological
proﬁles [2, 3].
Direct immunoﬂuorescence and serological indirect
immunoﬂuorescence have been for long time the main
tests utilised to diagnose autoimmune blistering conditions.
The recent availability of cDNA clones for pemphigus
antigens has allowed the production of recombinant DSG1
and DSG3 molecules and the development of an enzyme-
linked immunosorbent assay (ELISA) approach in order to
determine levels of antibodies to them [4, 5]. This assay has
shown a high sensitivity and speciﬁcity with respect to the
possibility to diagnose pemphigus and to diﬀerentiate PV
from PF. Patients with PV have circulating immunuglobulin
G (IgG) against DSG3 and DSG1 [6], whereas PF patients
only have anti-DSG1 IgG[7]. However, only few studies have
correlated DSG1 and DSG3 autoantibodies levels and disease
severity in PV.2 Clinical and Developmental Immunology
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Figure 1: Anti-DSG3 and anti-DSG1 autoantibody mean titres in
presence of mucosal involvement.
The aim of the study was to determine the relationship
betweenautoantibodieslevelsandtheextentofbothmucosal
and skin lesions in PV at the time of diagnosis and during
follow-up.
2.MaterialandMethods
The study comprised 20 caucasian patients with PV. The
diagnosis was made on the basis of clinic, histologic, and
immunopathologic criteria. We performed skin biopsies and
collected serum from these subjects at the time of diagnosis
and during follow-up. Hematoxylin-eosin stain and direct
immunoﬂuorescence were performed in each case.
For the detection of autoantibodies by ELISA we used
the recombinant proteins expressing overlapping sequences
with the entire extracellular DSG-1 and DSG-3 domains.
These antigens have been provided (Medical & Biological
Laboratories, Nagoya, Japan) as fusion proteins produced
by baculovirus in “High Five insect cell line” (DSG1 e
DSG3). Adding the serum of the patient to the recom-
binant proteins, we obtain an antigen-antibody reaction
which determinates in turn a colorimetric reaction, whose
adsorbance or optic density (OD) is noticed to 492nm by
an automatic spectrophotometry. ELISA was carried out
using an ELISA-kit containing the relevant recombinant
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Figure 2: Anti-DSG3 and anti-DSG1 autoantibody mean titres in
presence of skin involvement.
Table 1: Autoantibodies patterns at the time of diagnosis.
Exclusive skin
involvement
Exclusive mucous
involvement
Mucocutaneous
involvement
DSG1+ 15% 15% 30%
DSG3+
DSG1− / 20% 10%
DSG3+
DSG 1− /5 % 5 %
DSG 3−
proteins (Medical & Biological Laboratories) and proved to
be clinically reliable for the diagnosis of pemphigus vulgaris
and foliaceus [8]. Positive controls for DSG1 and DSG3
were a diluted standard pemphigus foliaceus and pemphigus
vulgaris serum, respectively. Negative control was diluted
standard serum obtained from normal individuals. The
cut-oﬀ values indicated by the manufacturer (autoantibody
titre ≥20Unit/mL) was used to discriminate positive from
negative results. Disease extent was arbitrarily assessed as
follows: no disease (−), mild disease (+) (less than 10% of
skin involvement; 1 or 2 mucosal lesions and no diﬃcultyClinical and Developmental Immunology 3
Table 2: Autoantibodies titres at the time of diagnosis (Unit/mL).
Patient DSG 1 titre DSG 3 titre Skin involvement Mucosal involvement
A.A. 17,43 7,95 + +
C.R. 16,8 1 — +
C.G. 1 30,66 —+ +
C.S. 86,92 168,43 ++ ++
D.A. 1 23,51 ++ ++
D.C. 1 140,9 —+ +
F.S. 140,97 250,17 +++ +++
I.S. 95,31 178,93 +++ +++
L.M.C. 67,46 210,66 —+ +
P.B. 28,43 142,86 —+ +
P.E. 4,82 72 ++ +
R.D. 74,52 161.04 — +++
R.L. 179,55 222,7 +++ +++
R.S. 3,96 169,69 —+ +
S.F. 144 148,93 ++ ++
T.E. 3,35 38,34 —+
V.I. 62,82 107,21 +++ +++
V.M. 85,19 106,25 +++ —
V.L. 66,46 39,38 ++ —
Z.P. 126,74 41,08 +—
in solid/liquid intake), moderate disease (++) (between 10
and 25% of skin involvement; 3–5 mucosal lesions and/or
diﬃculty in solid intake), and severe disease (+++) (more
than 25% of skin involvement; 6 or more mucosal lesions
and/or diﬃculty in liquid intake). In presence of mucosal
and/or skin lesions, Spearman’s rank correlation test was
used to correlate disease extent and autoantibodies titres. A
P value of <.05 was considered signiﬁcant. Analyses were
performed using the EPI-Info (Centers for Disease Control
of Atlanta, GA, USA).
3. Results
PV limited entirely to the mucosal surfaces was seen
in both DSG3+/DSG1− patients and DSG3+/DSG1+
patients. Mucocutaneous involvement was observed in both
DSG3+/DSG1− and DSG3+/DSG1+ patients, whereas PV
limited entirely to the cutaneous surfaces was seen only in
DSG3+/DSG1+. More precisely, a pattern of autoantibod-
ies DSG3+/DSG1− was observed in 30% of patients, all
showingamucousormucocutaneousinvolvement;apattern
DSG3+/DSG1+ was observed in 60% of patients, all with PV
and involvement of the mucous membrane and/or skin. Two
patients (one with mucous PV and one with mucocutaneous
PV) showed a double negative DSG3−/DSG1− phenotype.
In the 20 patients of the control group no one was positive
for autoantibodies against DSG1, whereas one was positive
for autoantibodies against DSG3. Autoantibodies patterns at
the time of the diagnosis and IgG titres are summarized in
Tables 1 and 2,r e s p e c t i v e l y .
3.1. Autoantibodies Titres and Extent of Disease at the
Time of Diagnosis. In presence of anti-DSG3 antibody titres
above 20Unit/mL, the mucosal involvement at the time of
diagnosis was absent in 16,7% of patients, mild in 5,5%
of patients, moderate in 50% of patients, and severe in
27,8% of patients. In patients with PV and positivity for the
presence of anti-DSG3 autoantibodies, the skin involvement
at the time of diagnosis was absent in 38,9% of patients,
mild in 11,1% of patients, moderate in 22,2% of patients,
and severe in 27,8% of patients. In patients with PV and
positivity for the presence of anti-DSG1 autoantibodies, the
mucosal involvement at the time of diagnosis was absent in
25% of patients, moderate in 33,3% of patients, and severe
in 41,7% of patients. In patients with PV and positivity
for the presence of anti-DSG1 autoantibodies, the skin
involvement was absent in 25% of patients, mild in 8,3%
of patients, moderate in 25% of patients, and severe in
41,7% of patients. In presence of mucosal lesions there was
a correlation between extension of mucosal involvement and
autoantibodies titres against both DSG-1 and DSG-3 (resp.,
P = .001 and P = .006), whereas in presence of skin lesions
there was a correlation between extension of skin lesions and
autoantibodies titres only against DSG-3 (P = .009), but not
against DSG-1 (P = .102) (Figures 1 and 2).
3.2.AutoantibodiesTitresandExtentofDiseaseduringFollow-
Up. 13 patients repeated the test at least twice during follow-
up. Results are summarized in Table 3. A not negligible
number of patients showed variations of the DSG-3 autoan-
tibodies titre which did not correlate with the extent of4 Clinical and Developmental Immunology
Table 3: Autoantibodies titres during follow-up. Values above the cutoﬀ point of 20Unit/mL are indicated in bold.
Name Date DSG 1 DSG 3 Skin Mucosal
16/12/03 17,43 7,95 + +
A.A. (PV mucocutaneous) 24/04/04 94.56 26,09 ++
20/01/05 60.9 21,92 —+
22/03/07 16,80 1 — +
C.R. (PV mucous) 12/04/07 20,26 54,67 —+
25/10/07 1 2,77 — —
20/12/06 1 30,66 —+ +
C.G. (PV mucous) 06/06/07 0 63,13 ——
31/10/07 0 122,82 ——
C.S. (PV mucocutaneous)
14/03/05 86,92 168,43 ++ ++
18/10/06 98,42 198,97 ++ —
F.S. (PV mucocutaneous)
04/09/03 140,97 250,17 +++ +++
27/11/03 25,76 189,19 +—
02/03/04 0 200,1 ——
26/08/04 0 34,28 ——
20/12/04 0 54,52 ——
07/05/05 1 90,22 ——
05/09/05 0 75,99 ——
13/01/06 1,29 85,7 ——
P.E. (PV mucocutaneous)
19/09/04 4,82 72 ++ +
01/09/05 1,4 64 —+
21/12/05 74,52 161,04 — +++
R.D. (PV mucous) 07/03/06 19,06 121,32 —+ +
18/10/06 3 179,78 ——
03/12/03 179,55 222,7 +++ +++
19/12/03 0 140,06 +++ +++
19/01/04 50,88 114,4 ++ ++
27/02/04 38 143,9 ++ —
03/06/04 165,27 164,95 ++ —
R.L. (PV mucocutaneous) 14/03/05 88,21 95,69 +—
18/05/05 135,38 131,07 +—
20/06/06 106,61 140,48 +—
04/10/06 148,44 159,12 ++ —
24/01/07 113,63 139,87 +—
30/05/07 124,23 154 ++ —
09/03/05 3,96 169,69 —+ +
R.S. (PV mucous) 23/05/07 0 256,8 —+ +
19/03/08 0 175,69 —+
T.E. (PV mucous)
01/09/06 3,35 38,34 —+
28/02/07 1 26,58 ——
17/12/07 62,82 107,21 +++ +++
V.I. (PV mucocutaneous) 06/02/08 56,73 193,26 +++ ++
13/05/08 27,59 179,46 +—Clinical and Developmental Immunology 5
Table 3: Continued.
Name Date DSG 1 DSG 3 Skin Mucosal
V.M. (PV cutaneous)
Transition from pemphigus
vulgaris to pemphigus
foliaceous
26/10/06 85,19 106,25 +++ —
23/05/07 190 0+ +—
16/05/08 144,6 0+—
Z.P. (PV cutaneous)
Transition from pemphigus
vulgaris to pemphigus
foliaceous
29/06/05 126,74 41,08 +—
09/11/05 74,11 10 + —
15/03/06 115,53 9,07 ++ —
26/07/06 163,34 17,78 ++ —
14/03/07 80,48 11,87 + —
both cutaneous and mucosal involvement. Similar results
were obtained analyzing autoantibodies titres against DSG-
1 which unconstantly correlated with the extent of both
mucosal and cutaneous disease.
In particular, there were some patients that continued to
have high titers of autoantibodies against DSG-3, although a
complete clinical remission in both cutaneous and mucosal
compartments. It is interesting to note that we observed
two patients with PV with only cutaneous involvement (VM
and ZP) that showed a shift in autoantibodies proﬁle from
DSG3+DSG1+ to DSG3−DSG1+ which was clinically and
histologically accompanied by a transition from PV to PF.
This conﬁrms the utility of this approach in the distinction
of these two subgroups of pemphigus.
4. Discussion
Theaimofourstudywastoestablishthepossibleexistenceof
a correlation between the extent of the disease at the time of
diagnosis and the titre of autoantibodies against DSG1 and
DSG3. Additionally, we investigated autoantibodies status
during follow-up.
In our study, we observed a wide range of titres
of autoantibodies against the recombinant protein DSG3;
however the general tendency indicated that antibodies
levels against DSG3 were more elevated in patients with
moderate and severe skin and/or mucosal involvement if
compared with patients with mild involvement. With regard
toanti-DSG-1antibodieswecoulddemonstrateastatistically
signiﬁcant correlation between antibody serum levels and
severity of mucosal involvement; there appears also to be a
correlation between the severity of skin involvement and the
level of DSG1 antibodies, although it was not statistically
signiﬁcant. Taken together, our ﬁndings are only partially
in accordance with the study by Harman et al. [9]w h o
found that levels of antibodies to DSG1 correlated with an
increase in the severity of skin involvement, but not with
the severity of mucosal involvement. The diﬀerence between
the present investigation and the study by Harman et al.
could be due to diﬀerent criteria utilised for calculating the
severity of disease. To this regard, it is possible that some
aspects of disease severity (such as doses of medications
required to control the disease) have not been captured by
the simple evaluation of disease extent. Low power of sample
size and racial diﬀerences between patients included in the
studies [10] could also be responsible of these discrepancies
indicatingtheneedofadditionallargesamplestudies.Onthe
other hand, the data presented in our study unequivocably
show that there is a not negligible number of patients
whose clinical presentation does not correlate with anti-DSG
antibody titres. Consequently, therapeutic interpretation of
this ELISA approach should be cautious.
From an immunopathogenetic point of view, the reasons
for the presence of patients whose disease extent did not
correlate with anti-DSG antibody titres, particularly anti
DSG-1, are unclear. It is possible that antibodies against
DSG1 recognize desmosomal antigens which are variable
exposed in the epidermis in the initial phases of the
condition, whereas the desmosomal antigen recognized by
anti-DSG3 antibodies is expressed in the mucosa epithelium
and skin at a more constant level.
We also investigated if patients with PV exhibited a
correlation between the course of mucosal and skin lesions
and variations of antibodies titre. We observed that there was
no a preponderance of patients that showed a correlation
between variation in the extent of the disease and the level
of autoantibodies against DSG3 and DSG1. In particular, we
observed some patients with signiﬁcative ELISA values for
autoantibodies against DSG3, who had responded to therapy
andwereincompleteremissionwithoutmucosaland/orskin
involvement. This is consistent with a recent investigation
[11] and indicates that autoantibodies against the extracel-
lular domains of this molecule are not always responsible
of the disease; it is plausible that they may represent
an epiphenomenon of an autoimmune reaction involving
pathogenetic antibodies to nondesmoglein molecules or to
the intracellular domain which are undetectable using our
ELISA approach [12]. Characteristically, no positive values
of DSG1 antibodies were observed in patients without
clinical manifestations of the disease indicating that clinical
remission coincides with a negative serology for these
autoantibodies.
The autoantibodies against DSG-1 and DSG-3 may be
inducedinselectedcircumstancesbyamechanismofepitope
spreading which may explain those cases negative for these
autoantibodies at the time of diagnosis (CR and AA see
Table 1) which subsequently developed them. It remains
also to be established the signiﬁcance of their presence in6 Clinical and Developmental Immunology
patients with a complete clinical remission and absence of
antigen exposition from lesional skin and/or mucosal tissue
in relation to a future relapse of the disease.
Finally, in our investigation we have conﬁrmed that this
analysis is high speciﬁc to detect a change in the clinical
phenotype of pemphigus. This was well evident in two
patients where a serological shift from DSG3+/DSG1+ to
DSG3−/DSG1+ was accompanied by a clinical transition
from PV to PF. This is in line with our previous observation
showing transition from PF to PV conﬁrmed by a serologi-
cally shift from DSG3−DSG1+ to DSG3+DSG1+ [13]. It is
interesting to note that in the present study this transition
wasobservedinpatientswithPVwithanexclusivecutaneous
involvement.
In conclusion, we believe that the utilization of recom-
binant DSG1 and DSG3 proteins by ELISA should be used
with caution to monitor disease severity and response to
therapy, although it remains a high speciﬁc test for the initial
diagnosis of pemphigus and the identiﬁcation of a change in
the clinical phenotype of this condition.
References
[1] C. Sitaru and D. Zillikens, “Mechanisms of blister induction
by autoantibodies,” Experimental Dermatology, vol. 14, no. 12,
pp. 861–875, 2005.
[ 2 ]S .W .Y e h ,B .A h m e d ,N .S a m i ,a n dA .R a z z a q u eA h m e d ,
“Blistering disorders: diagnosis and treatment,” Dermatologic
Therapy, vol. 16, no. 3, pp. 214–223, 2003.
[3] J.-C. Bystryn and J. L. Rudolph, “Pemphigus,” The Lancet, vol.
366, no. 9479, pp. 61–73, 2005.
[ 4 ]P .L e n z ,M .A m a g a i ,B .V o l c - P l a t z e r ,G .S t i n g l ,a n dR .K i r n -
bauer, “Desmoglein 3-ELISA: a pemphigus vulgaris-speciﬁc
diagnostic tool,” Archives of Dermatology, vol. 135, no. 2, pp.
143–148, 1999.
[5] M. Amagai, A. Komai, T. Hashimoto, et al., “Usefulness
of enzyme-linked immunosorbent assay using recombinant
desmogleins 1 and 3 for serodiagnosis of pemphigus,” British
Journal of Dermatology, vol. 140, no. 2, pp. 351–357, 1999.
[6] V. K. Sharma, H. R. Y. Prasad, S. Khandpur, and A. Kumar,
“Evaluation of desmoglein enzyme-linked immunosorbent
assay (ELISA) in Indian patients with pemphigus vulgaris,”
International Journal of Dermatology, vol. 45, no. 5, pp. 518–
522, 2006.
[7] M. Amagai, K. Tsunoda, D. Zillikens, T. Nagai, and T.
Nishikawa, “The clinical phenotype of pemphigus is deﬁned
by the anti-desmoglein autoantibody proﬁle,” Journal of the
American Academy of Dermatology, vol. 40, no. 2, pp. 167–170,
1999.
[ 8 ]K .E .H a r m a n ,M .J .G r a t i a n ,P .T .S e e d ,B .S .B h o g a l ,S .J .
Challacombe, and M. M. Black, “Diagnosis of pemphigus by
ELISA: a critical evaluation of two ELISAs for the detection
of antibodies to the major pemphigus antigens, desmoglein 1
and 3,” Clinical and Experimental Dermatology, vol. 25, no. 3,
pp. 236–240, 2000.
[ 9 ]K .E .H a r m a n ,P .T .S e e d ,M .J .G r a t i a n ,B .S .B h o g a l ,S .J .
Challacombe, and M. M. Black, “The severity of cutaneous
a n do r a lp e m p h i g u si sr e l a t e dt od e s m o g l e i n1a n d3a n t i b o d y
levels,” British Journal of Dermatology, vol. 144, no. 4, pp. 775–
780, 2001.
[ 1 0 ]K .E .H a r m a n ,M .J .G r a t i a n ,B .S .B h o g a l ,S .J .C h a l l a c o m b e ,
and M. M. Black, “A study of desmoglein 1 autoantibodies
in pemphigus vulgaris: racial diﬀerences in frequency and the
association with a more severe phenotype,” British Journal of
Dermatology, vol. 143, no. 2, pp. 343–348, 2000.
[11] C. Abasq, H. Mouquet, D. Gilbert, et al., “ELISA testing of
anti-desmoglein 1 and 3 antibodies in the management of
pemphigus,” Archives of Dermatology, vol. 145, no. 5, pp. 529–
535, 2009.
[12] S. W. Cheng, M. Kobayashi, A. Tanikawa, K. Kinoshita-
Kuroda, M. Amagai, and T. Nishikawa, “Monitoring disease
activity in pemphigus with enzyme-linked immunosorbent
assay using recombinant desmogleins 1 and 3,” British Journal
of Dermatology, vol. 147, no. 2, pp. 261–265, 2002.
[13] B. Pigozzi, A. Peserico, L. Schiesari, and M. Alaibac, “Pem-
phigus foliaceus evolving into pemphigus vulgaris: a probable
example of ‘intermolecular epitope spreading’ conﬁrmed by
enzyme-linked immunosorbent assay study,” Journal of the
European Academy of Dermatology and Venereology, vol. 22,
no. 2, pp. 242–244, 2008.